Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.
about
The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapyMechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cellsATP-Binding Cassette Genes Genotype and Expression: A Potential Association with Pancreatic Cancer Development and Chemoresistance?Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.tRNA modifying enzymes, NSUN2 and METTL1, determine sensitivity to 5-fluorouracil in HeLa cellsNab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoproteinCell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthaseMolecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes.Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine.Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinomaSystemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapyA tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsThe autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model.The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.Bisdemethoxycurcumin exerts pro-apoptotic effects in human pancreatic adenocarcinoma cells through mitochondrial dysfunction and a GRP78-dependent pathway.Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer.Imaging transporters: Transforming diagnostic and therapeutic development.Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.Inhibitory effect of geraniol in combination with gemcitabine on proliferation of BXPC-3 human pancreatic cancer cells.Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer.Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.Antimicrobial evaluation of new synthesized pyridine nucleosides under solvent-free conditions.Pancreatic Cancer Chemoresistance to Gemcitabine.Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells.
P2860
Q26830005-DB636E5B-8455-495A-858B-E9F154C9C942Q28485201-05775DF7-5EC5-40D0-A23A-6D28DE92181DQ33634888-9D7A28AF-6F8D-48D6-AFD6-3254E78E7D05Q33887021-0B3D5361-395B-4D73-89BE-DD01D88C1897Q34214788-C10B050A-EAC2-4CEB-902B-A80A0CD5A95CQ34422252-7A822B0B-AEA5-49A3-A075-34A8FE3DD60CQ34555685-5737A7BF-B652-4C52-9E3A-F1039BCC554EQ35161704-2B875FA8-B3A2-4E4D-A215-1D5F0373A5C1Q35768413-F80B9BA7-100A-4A95-BC73-10B3011EE4F2Q36094941-A3C6877F-8FDC-46A1-B0C9-672BE786A8C6Q36156256-812CEA4C-2794-40D5-BCAE-7DEB6F82DBF8Q36246425-4D0D919C-D0BB-41D3-8613-B203F88B62C4Q36693506-34351B02-B7EC-47FD-AB0A-85D0A0A24B7FQ36740744-F8A2FB7B-A00F-4BFF-9E42-30FDB3F328F3Q37194819-CB76E94A-8BA3-4876-8F53-57986946BEA0Q37688898-8D2FCC3C-1C1F-4B8F-BBCC-62E1D014B13BQ37696356-138E1D2F-C160-4628-B528-3EFB7544CC8CQ38125770-5CE06FC6-D15D-44F5-A751-26E7EE664425Q38694488-A541E230-3BA7-4F7B-BCA9-BD5DC4E807F3Q38718324-E4D0B699-C0E5-40B4-A0DC-E23CDAD6B1E9Q38847679-AF838561-B684-431F-A1AB-311CE49D7B89Q38871905-E3B8B59F-F1B8-4C13-BFF5-68B4170991DDQ38945152-9F5EAD2C-D819-4952-8864-0A8A96B00D38Q39035732-48F18304-6BD3-42E5-96D7-048BE22D51ADQ39134968-409FF506-BD33-43E5-ADC3-FF90D6237D9FQ41366826-AC5E5633-7812-4689-A490-6D2CFF2643D9Q42406267-3A675BB2-008B-4471-98C7-B4DE0628B1F3Q45323990-17477383-102B-4C95-87CE-A9FA489E5C0CQ47135556-1EDAF7AF-A24F-4A26-8A86-625F5AE0A70DQ49491161-245520EF-24FB-4325-9E79-98F8EC1B0BA3Q52665635-2CAE2FEF-6410-4501-A72B-AB3E48BF1CF5
P2860
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Overcoming nucleoside analog c ...... ncer: a therapeutic challenge.
@en
Overcoming nucleoside analog c ...... ncer: a therapeutic challenge.
@nl
type
label
Overcoming nucleoside analog c ...... ncer: a therapeutic challenge.
@en
Overcoming nucleoside analog c ...... ncer: a therapeutic challenge.
@nl
prefLabel
Overcoming nucleoside analog c ...... ncer: a therapeutic challenge.
@en
Overcoming nucleoside analog c ...... ncer: a therapeutic challenge.
@nl
P2093
P2860
P1433
P1476
Overcoming nucleoside analog c ...... ncer: a therapeutic challenge.
@en
P2093
Hardik R Mody
Rajgopal Govindarajan
Sau Wai Hung
P2860
P304
P356
10.1016/J.CANLET.2012.03.007
P407
P577
2012-03-13T00:00:00Z